Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Revita in Obesity, Type 2 diabetes. The expected timing is based on the latest available company guidance and may change.
REMAIN-1, REVEAL-1 trials. 4/1/25- REVEAL-1 prelim data reported. 6/23/25- 3mth REVEAL-1 cohort data reported. 9/26/25- REMAIN-1 Midpoint cohort 3mth data announced; met key efficacy endpoint. 6mth primary endpoint data in Q1 2026. REMAIN-1 Pivotal cohort 6mth endpoint data in H2 2026. 11/12/25:- Revita randomized REMAIN-1 data positive; Germany registry 2-year outcomes favorable; multiple cohort data catalysts Q4 2025–H2 2026. 01/29/26:- 6m Midpoint data positive. 1y REVEAL-1 Q2 2026, 1y Midpoint Q3 2026, pivotal 6m and FDA filing H2 2026. 02/26/26:- REMAIN-1 Pivotal randomization completed; De Novo feedback Q2 2026; pivotal 6m data early Q4 2026; filing late Q4 2026. 03/24/26:- New Midpoint post-hoc data; pivotal randomization complete; Q2–Q4 2026 REVEAL-1, Midpoint, pivotal 6m and De Novo milestones. 05/12/26:- Revita Q2–Q4 2026 REVEAL-1, Midpoint, pivotal 6m data and late Q4 2026 De Novo submission timelines reaffirmed. 06/04/26:- REVEAL-1 1y weight maintenance positive. Next REMAIN-1 Midpoint 1y data Q3 2026; Pivotal 6m topline Early Q4 2026. 07/15/26:- REMAIN-1 Midpoint Cohort 1y results positive. Pivotal 6m topline Early Q4 2026; De Novo filing Late Q4 2026. 08/10/26:- One-year data were detailed. Pivotal 6m expected Early Q4 2026, De Novo Late Q4, 1y Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.